# Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

> **NCT05402722** · PHASE2 · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 30 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Eribulin
- **DRUG:** anti-PD-1 antibody

## Key facts

- **NCT ID:** NCT05402722
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05402722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05402722, "Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05402722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*